How to Evaluate a Peptide Clinic

The peptide clinic you choose matters as much as the peptide itself. As of late 2024, the FDA's adverse event database listed over 900 reports linked to compounded semaglutide and tirzepatide alone — including 17 deaths.^[1] Many of those cases traced back not to the molecule, but to dosing errors, contamination, or absent medical oversight. The FDA has issued 80+ warning letters to GLP-1 compounders and telehealth firms since September 2025, and DOJ criminal prosecutions have shut down multiple vendors who were selling mislabeled or adulterated products.^[2]

None of this means peptide therapy is inherently dangerous. It means the provider layer — the prescriber, the pharmacy, the follow-up — is where risk concentrates. This guide gives you a practical framework for evaluating that layer before you start.

The prescriber: what to verify

The person writing your prescription is the first line of quality control. Here's what to look for — and how to check.

Are they actually licensed?

Peptides should be prescribed by a licensed MD, DO, NP, or PA with prescribing authority in your state. This is non-negotiable. Every state maintains a public database where you can verify a prescriber's license status, education, and any disciplinary actions.^[11]

How to check:

• Doctors (MD/DO): Search your state medical board's license verification tool. The Federation of State Medical Boards maintains links to every state board, and DocInfo.org provides a national aggregated search.^[11]
• Nurse practitioners and physician assistants: Check your state's board of nursing or physician assistant licensing board. These are separate from the medical board in most states.
• What to look for: Active license status, no unresolved disciplinary actions, and appropriate credentials for prescribing controlled or compounded medications.

If a clinic won't tell you who the prescribing provider is, or if the provider's name doesn't appear in any state licensing database, stop there.

Do they require a real consultation?

A thorough initial consultation is the minimum standard of care. This means more than a checkout form with a few yes/no questions.

What good looks like:

• A live consultation (video or in-person) lasting 15+ minutes
• Review of your medical history, current medications, and health goals
• Discussion of contraindications and potential side effects specific to you
• A clear explanation of what's being prescribed and why

What should give you pause:

• Asynchronous-only questionnaires with no live provider interaction
• A "consultation" that takes less than five minutes
• No questions about your medical history or current medications

Do they require lab work?

For many peptides — especially GLP-1 agonists, growth hormone secretagogues, and hormonal peptides — baseline lab work is part of responsible prescribing. Labs help the provider identify contraindications, establish baselines, and monitor your response over time.

Typical baseline labs might include: metabolic panel, thyroid function, HbA1c, lipid panel, IGF-1 (for GH-related peptides), or CBC depending on the peptide and your health profile.

Not every peptide requires extensive labs. But if a clinic prescribes injectable peptides without asking about any lab work or health screening, that's a gap in the standard of care.

Is there a follow-up schedule?

Prescribing is not a single transaction — it's the beginning of a clinical relationship. Responsible providers build in follow-up touchpoints to assess your response, adjust dosing, and catch adverse effects early.

What good looks like:

• Scheduled check-ins (every 4-8 weeks during titration, then quarterly)
• Clear instructions on how to report side effects between visits
• Lab monitoring at defined intervals

What should concern you:

• No follow-up system at all — the prescription renews automatically without any clinical review
• Follow-up is "available on request" but never proactively scheduled
• Refills are processed without anyone asking how you're doing

The compounding pharmacy: 503A vs 503B

If your peptide is compounded (not a brand-name FDA-approved product), the pharmacy that makes it matters enormously. Not all compounding pharmacies operate under the same rules.

503A pharmacies: traditional compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. These pharmacies:

• Compound medications based on individual patient-specific prescriptions
• Are primarily regulated by state boards of pharmacy, not the FDA
• Follow USP compounding standards (USP ⟨795⟩ for non-sterile, USP ⟨797⟩ for sterile)^[8][9]
• Cannot produce large batches for general distribution
• Do not require FDA registration

The quality of a 503A pharmacy depends heavily on your state's board of pharmacy and the pharmacy's own commitment to standards. Oversight varies significantly from state to state.

503B pharmacies: outsourcing facilities

Section 503B created a category called "outsourcing facilities." These pharmacies:

• Can compound medications in larger batches, including without patient-specific prescriptions
• Must register with the FDA and are subject to FDA inspections^[3]
• Must follow current Good Manufacturing Practices (cGMP) — the same manufacturing standards as pharmaceutical companies
• Must submit every batch for testing before release
• Must report adverse events to the FDA

The key difference: 503B facilities face federal-level manufacturing and quality standards, while 503A pharmacies rely primarily on state oversight.

Why this matters for you

A 503B outsourcing facility offers more built-in quality assurance: FDA registration, cGMP compliance, batch testing, and adverse event reporting. That doesn't mean every 503A pharmacy is substandard — many are excellent — but the floor for quality is structurally higher in the 503B model.

How to verify a compounding pharmacy

• For 503B facilities: Check the FDA's list of registered outsourcing facilities. You can confirm a pharmacy's registration status and review any FDA inspection results.^[3]
• For 503A and 503B: Check your state board of pharmacy for an active license.
• PCAB accreditation: The Pharmacy Compounding Accreditation Board (administered by ACHC) offers voluntary accreditation that requires annual verification, independent on-site inspections, and adherence to standards that exceed baseline state requirements.^[12] PCAB accreditation is a meaningful quality signal for both 503A and 503B pharmacies.
• PCCA membership: Membership in the Professional Compounding Centers of America indicates access to quality-tested ingredients and continuing education, though it's not an accreditation.

Quality indicators to look for

Beyond the prescriber and pharmacy, there are signals that distinguish careful operations from careless ones.

Certificates of Analysis (COAs)

A COA is a document from the compounding pharmacy (or their ingredient supplier) that reports the results of quality testing on a specific batch. It typically includes peptide identity confirmation, purity (via HPLC), potency, sterility testing results, and endotoxin levels.

What good looks like: The clinic or pharmacy provides COAs on request, or proactively shares them. The COA references a specific lot/batch number that matches what you received.

What should concern you: The clinic has never heard of a COA. Or they provide a generic document that doesn't reference your specific product's batch number.

For a detailed guide on reading and verifying COAs, see our COA verification guide.

Transparent sourcing

Reputable clinics identify their pharmacy partners by name. You should be able to verify that the pharmacy exists, holds the appropriate licenses, and operates under either 503A or 503B regulations.

Pricing transparency

Are consultation fees, medication costs, supply costs, and follow-up fees clearly listed? Or does the sticker price only cover the medication, with surprise fees for "required" add-ons?

Legal product selection

Does the clinic offer only peptides that can be legally compounded? As of 2026, several popular peptides — including BPC-157, TB-500, Epitalon, and DSIP — are on the FDA's Category 2 list, meaning they cannot legally be compounded by 503A or 503B pharmacies due to unresolved safety concerns.^[4] A clinic that offers Category 2 peptides through a U.S. compounding pharmacy is either sourcing from non-compliant pharmacies or from the gray market.

Adverse event reporting

Does the clinic have a clear process for you to report side effects? 503B pharmacies are required to report adverse events to the FDA. But even with 503A pharmacies, a responsible clinic should have a system for documenting and responding to adverse reactions — not just for regulatory compliance, but because it's good medicine.^[1]

Red flags scorecard

Use this as a quick-reference checklist when evaluating a peptide provider. No single yellow flag is disqualifying, but multiple yellow flags — or any red flag — should prompt serious questions.

---

---

Pricing transparency

Peptide therapy through a legitimate clinic involves real costs: a licensed prescriber's time, quality-tested medications from an accredited pharmacy, supplies, and follow-up care. Here's what reasonable looks like.

Typical price ranges (2025-2026)

What suspiciously low prices might mean

If a clinic's pricing is dramatically below these ranges, it's worth asking why. Common explanations include:

• The pharmacy is cutting corners on sterility testing, ingredient quality, or cGMP compliance^[8]
• There's no real prescriber involvement — you're paying for a product, not medical care
• The peptide isn't what it claims to be — independent testing has shown that 43% of gray-market peptides fail purity standards, and up to 23% of some peptides (like retatrutide) have contained the wrong molecule entirely^[6]
• Follow-up care isn't included — the low price covers only the medication, with no clinical oversight

High prices don't guarantee quality either. But prices far below the market should trigger the same due diligence you'd apply to any too-good-to-be-true offer.

Ten questions to ask before starting

Before committing to a peptide provider, ask these questions. The answers — and how willingly they're given — tell you a lot.

1. Who is my prescribing provider, and what are their credentials? A good answer names a specific licensed clinician. A concerning answer is vague or evasive.^[11]

2. Will I have a live consultation before anything is prescribed? You want a real clinical evaluation, not just a checkout flow.

3. What lab work do you require before starting, and how often do you recheck? Look for specifics: which labs, at what intervals, and what they're monitoring for.

4. Which compounding pharmacy fills your prescriptions? The pharmacy should be named. You should be able to verify its license and registration independently.^[3]

5. Is your pharmacy a 503A or 503B facility? Either can be appropriate, but you should know which regulatory framework applies. If they don't know the answer, that's a problem.

6. Can I see a Certificate of Analysis for my specific batch? A COA with a lot number that matches your product is the gold standard. If they can't produce one, ask why.

7. What is your follow-up schedule, and how do I report side effects? Look for proactive check-ins, not just a support email address.

8. What's included in the price? Consultation, medication, supplies, shipping, follow-up — or are those billed separately?

9. Are the peptides you offer legally compoundable under current FDA regulations? This matters. If a clinic is offering Category 2 substances (like BPC-157 or TB-500) through a U.S. compounding pharmacy, the supply chain may not be what they're representing.^[4]

10. What happens if I have an adverse reaction? You want a clear protocol: who to contact, how quickly they respond, and whether adverse events are documented and reported.

Compounded vs FDA-approved: when the choice matters

Not all peptides are created equal from a regulatory standpoint, and understanding the distinction helps you evaluate what a clinic is offering.

When an FDA-approved version exists

For semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), FDA-approved versions are available. These products have been tested in large clinical trials — semaglutide's SELECT trial enrolled over 17,600 patients — and are manufactured under full FDA oversight.^[10]

Why some people still choose compounded versions:

• Cost: FDA-approved GLP-1 medications can run $1,000+/month without insurance. Compounded versions typically cost $200–$600/month.
• Dose flexibility: Compounded formulations can be prepared in custom doses for slower titration.
• Access: Insurance coverage for weight management indications remains inconsistent.

The tradeoffs:

• Compounded semaglutide often uses different salt forms (sodium or acetate) than the FDA-approved product. The FDA has noted these may have different pharmacological properties.^[1]
• Quality depends entirely on the compounding pharmacy. The 520+ adverse event reports and dosing errors linked to compounded semaglutide products underscore this.^[1]
• You lose the manufacturing consistency, post-marketing surveillance, and regulatory accountability that come with FDA-approved products.

If cost is the primary driver, the calculus is straightforward: a compounded product from a reputable 503B pharmacy with COAs is a reasonable option for many people. But go in with clear eyes about what you're trading for the savings.

When no FDA-approved version exists

For peptides like BPC-157, TB-500, CJC-1295, ipamorelin, and many others, there is no FDA-approved version. These molecules have never been through the full clinical trial and regulatory approval process in the United States.

For peptides that remain on the FDA's Category 1 list (eligible for compounding), a licensed compounding pharmacy is the only legal supply route. For Category 2 peptides (BPC-157, TB-500, Epitalon, DSIP), legal compounding in the U.S. is currently prohibited — meaning any supply is coming from either offshore sources or non-compliant pharmacies.^[4]

This doesn't mean these peptides are worthless. It means the evidence base is thinner, the quality control infrastructure is weaker, and the risk profile is less well-characterized. Your choice of provider matters even more in this context, because there are fewer guardrails built into the system.

---

Related content

Peptide

Semaglutide

The most-prescribed peptide therapeutic. Understanding clinic quality matters most for FDA-approved compounds.

Peptide

Tirzepatide

A dual-action GLP-1/GIP agonist increasingly offered at peptide clinics. Full evidence profile.

Tool

Price Comparison Worksheet

Compare clinic and vendor pricing on a like-for-like basis, adjusted for purity and shipping.

Guide

How to Verify a COA

A practical guide to reading certificates of analysis — essential for evaluating any peptide source.

News

FDA Enforcement and the Gray Market

The FDA is cracking down on unregistered sellers. What it means for clinic sourcing.

Tool

COA Checklist and Red-Flag Checker

Score a COA against lot specificity, test methods, and injectable-relevant verification signals.

References

1. [1]

   U.S. Food and Drug Administration. “FDA's concerns with unapproved GLP-1 drugs used for weight loss.” 2025. Link

   FDA safety communication documenting adverse events from compounded semaglutide and tirzepatide products, including dosing errors requiring hospitalization.

2. [2]

   U.S. Food and Drug Administration. “Compounding risk alerts.” 2025. Link

   FDA enforcement actions and warning letters to compounding firms, including 50+ warnings to GLP-1 compounders in September 2025.

3. [3]

   U.S. Food and Drug Administration. “Registered outsourcing facilities.” 2025. Link

   Public database of FDA-registered 503B outsourcing facilities. Includes registration status and inspection history.

4. [4]

   U.S. Food and Drug Administration. “Certain bulk drug substances for use in compounding that may present significant safety risks.” 2024. Link

   Official FDA guidance on Category 1 and Category 2 bulk drug substances for compounding.

5. [5]

   U.S. Food and Drug Administration. “Class I recall: NAD+ for Injection (GenoGenix LLC) — elevated endotoxin levels.” 2025. Link

   Class I recall (most serious). Lot #GG121624-023 tested at 3,360 EU/mL. Three patients hospitalized.

6. [6]

   Janoshik Analytical. “Public peptide testing database — 2024 aggregate results.” 2024. Link

   Independent analytical testing laboratory (Prague). Found 43% of gray-market peptides failed purity claims; 23% of retatrutide samples contained exendin-4 analogs.

7. [7]

   Finnrick Analytics. “Peptide vendor testing database — 5,930 samples from 196 vendors.” 2025. Link

   US-based independent testing service (Texas). Identified quantity discrepancies up to 48% and endotoxin contamination in gray-market products.

8. [8]

   United States Pharmacopeia. “USP General Chapter ⟨797⟩ Pharmaceutical Compounding — Sterile Preparations.” 2025. Link

   Standard governing sterile compounding practices, including required testing, personnel training, and facility requirements.

9. [9]

   United States Pharmacopeia. “USP General Chapter ⟨795⟩ Pharmaceutical Compounding — Nonsterile Preparations.” 2025. Link

   Standard governing non-sterile compounding, including equipment, training, and quality assurance.

10. [10]

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. “Semaglutide and cardiovascular outcomes in obesity without diabetes.” N Engl J Med. 2023. 389:2221–2232 DOI PubMedRCT

    SELECT trial (n=17,604). The landmark cardiovascular outcomes trial for semaglutide in obesity.

11. [11]

    Federation of State Medical Boards. “DocInfo.org — physician verification tool.” 2025. Link

    National aggregated physician license verification database covering all US state medical boards.

12. [12]

    Accreditation Commission for Health Care (ACHC). “Pharmacy Compounding Accreditation Board (PCAB).” 2025. Link

    Voluntary accreditation for compounding pharmacies requiring annual verification, independent on-site inspections, and standards exceeding baseline state requirements.

---